| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Truefit.io provides comprehensive analytics and development solutions tailored to eCommerce businesses. They offer product recommendations, personalized styling, sizing tools and more to help online retailers increase customer engagement and drive reve...
Tekskills is a Edison, NJ-based company in the Software and Internet sector.
stromback media is a Auburn Hills, MI-based company in the Software and Internet sector.
Blockstack is a new internet for decentralized apps where users own their data. A browser is all that`s needed to get started.